A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.
Decisions about where and to whose professional stewardship patients are admitted are influenced by federal policies of which physicians might not be aware.
AMA J Ethics. 2023;25(12):E901-908. doi:
10.1001/amajethics.2023.901.
It is difficult to argue that consumers are maximizing their welfare by consuming trans fats, particularly because the production and taste costs of replacing them do not outweigh the health benefits.
Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.